King Luther Capital Management Corp Raises Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

King Luther Capital Management Corp increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 10.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 17,216 shares of the company's stock after acquiring an additional 1,619 shares during the period. King Luther Capital Management Corp owned about 0.06% of Medpace worth $5,747,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. O Shaughnessy Asset Management LLC bought a new stake in shares of Medpace in the first quarter worth $307,000. Natixis acquired a new stake in shares of Medpace in the first quarter valued at about $727,000. EntryPoint Capital LLC bought a new position in shares of Medpace during the first quarter worth about $54,000. Advisors Asset Management Inc. lifted its stake in shares of Medpace by 106.4% in the first quarter. Advisors Asset Management Inc. now owns 2,735 shares of the company's stock worth $1,105,000 after acquiring an additional 1,410 shares during the period. Finally, Canada Pension Plan Investment Board increased its position in Medpace by 15.9% during the 1st quarter. Canada Pension Plan Investment Board now owns 67,800 shares of the company's stock valued at $27,401,000 after purchasing an additional 9,300 shares during the period. Institutional investors and hedge funds own 77.98% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on MEDP. Robert W. Baird cut shares of Medpace from an "outperform" rating to a "neutral" rating and decreased their price objective for the stock from $413.00 to $349.00 in a research report on Wednesday, October 23rd. Truist Financial lowered their price objective on Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a research report on Monday, October 14th. UBS Group lowered Medpace from a "buy" rating to a "neutral" rating and cut their target price for the company from $420.00 to $350.00 in a research report on Friday, September 27th. Redburn Atlantic assumed coverage on shares of Medpace in a research report on Monday, October 14th. They set a "buy" rating and a $404.00 price objective for the company. Finally, StockNews.com downgraded shares of Medpace from a "buy" rating to a "hold" rating in a research report on Friday, September 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $380.00.

Medpace Trading Down 1.2 %

NASDAQ MEDP traded down $4.07 during trading hours on Friday, hitting $337.75. The company's stock had a trading volume of 351,389 shares, compared to its average volume of 285,250. The company has a market capitalization of $10.50 billion, a PE ratio of 30.32, a price-to-earnings-growth ratio of 1.74 and a beta of 1.37. Medpace Holdings, Inc. has a 52 week low of $268.80 and a 52 week high of $459.77. The company's 50-day simple moving average is $340.42 and its two-hundred day simple moving average is $373.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.24. The company had revenue of $533.32 million for the quarter, compared to analyst estimates of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the company earned $2.22 earnings per share. Research analysts anticipate that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.